NSE: BIOCON | BSE: 532523

Mid-range Performer

Download real time

335.60 1.25 (0.37%)

1.1M NSE+BSE Volume

NSE 29 May, 2025 3:31 PM (IST)

40,292.1

Market Cap

Market Leader

1.2

Beta 1Year

High Volatility

Biocon Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for BIOCON, BSE:532523 Biocon Ltd.

Biocon Ltd.

14 Jul 2017

335.60

0.37%

Biocon

Hold: Biocon Ltd.

ICICI Securities Limited

In a significant development that can be termed as a precursor for biosimilar launch in the US, the USFDA Oncologic Drugs Advisory Committee (ODAC) has strongly recommended approval of Biocon/Mylan's proposed biosimilar Trastuzumab, a biologically similar version of Roche's breast-cancer drug Herceptin. Herceptin is indicated to treat certain HER2-positive breast and gastric cancers. The committee voted 16-0 in support of eligible indications of the reference product. During the discussion, ODAC determined that no clinically meaningful...

Biocon Ltd. has an average target of 389.25 from 4 brokers.

Biocon Ltd.

20 May 2017

335.60

0.37%

Biocon Ltd Q4FY17 results comment

Results Update: Biocon Ltd.

HDFC Securities

Revenue fell by 10.1% to Rs. 919.2 Cr in Q4FY17 when compared to the previous quarter. Also it decreased by 1.53% when compared with Q4FY16.

Number of FII/FPI investors increased from 297 to 305 in Mar 2025 qtr.

Biocon Ltd.

02 May 2017

335.60

0.37%

Biocon

Hold: Biocon Ltd.

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues declined 1.5% YoY to | 931 crore (I-direct estimate: | 1055 crore) due to elongated approval timelines in emerging markets, discontinuance of in-licensed products and fire incident at Syngene EBITDA margins contracted 70 bps YoY to 20.1% (I-direct estimate: 25%) mainly due to higher raw material & employee cost. EBITDA declined 4.8% YoY to | 188 crore (I-direct estimate: | 264 crore) Net profit increased 106% YoY to | 127.5 crore (I-direct estimate:...

Number of FII/FPI investors increased from 297 to 305 in Mar 2025 qtr.

Biocon Ltd.

02 Feb 2017

335.60

0.37%

Result Update:Biocon

Hold: Biocon Ltd.

Axis Direct

Q3FY17 PAT (up 67% YoY) was 21% higher than our estimate due to 2.5x increase in licensing income (directly flows to PBT). While EBITDA margin improved to 25.7% (up 401 bps YoY), margin (ex-licensing) improved slightly (up 93 bps YoY) to 19.5%. Much-awaited Insulin facility in Malaysia is commercial..

Biocon Ltd. has an average target of 389.25 from 4 brokers.

Biocon Ltd.

31 Jan 2017

335.60

0.37%

Biocon Ltd Q3FY17 results comment

Results Update: Biocon Ltd.

HDFC Securities

Revenue grew by 9.7% to Rs. 1022.5 Cr in Q3FY17 when compared to the previous quarter. Also, it grew by 29.59% when compared with Q3FY16.

Number of FII/FPI investors increased from 297 to 305 in Mar 2025 qtr.

Biocon Ltd.

27 Jan 2017

335.60

0.37%

Biocon

Hold: Biocon Ltd.

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 29% YoY to | 1044 crore (I-direct estimate: | 996 crore) mainly due to a sharp jump in licensing income and robust growth in biologics. Licensing income increased to | 79 crore from | 32 crore in Q3FY16. Biologics revenues grew 60% to | 120 crore EBITDA margins improved 354 bps YoY to 26.4% (I-direct estimate: 24.2%) mainly due to lower raw material & other expenses. Higher licensing income was also contributed to EBITDA...

Number of FII/FPI investors increased from 297 to 305 in Mar 2025 qtr.

Biocon Ltd.

24 Oct 2016

335.60

0.37%

Biocon

Hold: Biocon Ltd.

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 19.8% YoY to | 954 crore (I-direct estimate: | 1043 crore) mainly due to higher licensing income & growth in biological business. Biological segment revenues grew 26.3% YoY to | 96 crore (I-direct estimate: | 120 crore) EBITDA margins improved 392 bps YoY to 25.2% (I-direct estimate: 23.9%) due to higher licensing income and lower R&D; expenses...

Biocon Ltd. is trading below its 100 day SMA of 345.4

Is Biocon Ltd. worth buying?

716 Votes:

Buy 75.14%

Sell 16.34%

Hold 8.52%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf